Lazard Asset Management’s Fate Therapeutics FATE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-89,403
| Closed | -$901K | – | 2378 |
|
|
2022
Q4 | $901K | Sell |
89,403
-71,970
| -45% | -$725K | ﹤0.01% | 1018 |
|
|
2022
Q3 | $3.62M | Sell |
161,373
-59,987
| -27% | -$1.34M | 0.01% | 774 |
|
|
2022
Q2 | $5.49M | Buy |
221,360
+76,571
| +53% | +$1.9M | 0.01% | 723 |
|
|
2022
Q1 | $5.61M | Buy |
144,789
+36,797
| +34% | +$1.43M | 0.01% | 736 |
|
|
2021
Q4 | $6.32M | Buy |
107,992
+62,310
| +136% | +$3.65M | 0.01% | 733 |
|
|
2021
Q3 | $2.71M | Sell |
45,682
-27,105
| -37% | -$1.61M | ﹤0.01% | 875 |
|
|
2021
Q2 | $6.32M | Buy |
72,787
+70,507
| +3,092% | +$6.12M | 0.01% | 686 |
|
|
2021
Q1 | $187K | Buy |
2,280
+697
| +44% | +$57.2K | ﹤0.01% | 1110 |
|
|
2020
Q4 | $143K | Buy |
+1,583
| New | +$143K | ﹤0.01% | 1136 |
|
|
2020
Q3 | – | Sell |
-117
| Closed | -$4K | – | 1645 |
|
|
2020
Q2 | $4K | Buy |
+117
| New | +$4K | ﹤0.01% | 1532 |
|